Corrigendum: Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach

Frontiers in Oncology

Jing Ze Li¹  Alfredo Franco-Obregón⁵  Jasmine Lye Yee Yap⁶  Charlene Hui Hua Fong⁶  Karen Ka Wing Chan⁶  Sharanya Ramanan⁶  Yee Kit Tai⁶  Jocelyn Naixin Yin⁶  Angele Pei Fern Koh⁷  Ruby Yun Ju Huang⁸  Ching Wan Chan^1,11  Jürg Fröhlich^1,12  Wei Ren Tan^1,13  Yun Sheng Yip^1,13  Nguan Soon Tan^1,14 

[1]Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

[2]Technology (iHealthtech), National University of Singapore, Singapore, Singapore

[3]0Institute of Electromagnetic Fields, ETH Zürich (Swiss Federal Institute of Technology in Zürich), Zürich, Switzerland

[4]

[5]1Institute for Health Innovation &2Competence Center for Applied Biotechnology and Molecular Medicine, University of Zürich, Zürich, Switzerland

[6]Biolonic Currents Electromagnetic Pulsing Systems Laboratory (BICEPS), National University of Singapore, Singapore, Singapore

[7]Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore

[8]

[9]Department of Obstetrics &Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

[10]Division of General Surgery (Breast Surgery), Department of Surgery, National University Hospital, Singapore, Singapore

[11]Division of Surgical Oncology, National University Cancer Institute, Singapore, Singapore

[12]Fields at Work GmbH, Zürich, Switzerland

[13]Lee Kong Chian School of Medicine, Nanyang Technological University Singapore, Singapore, Singapore

[14]School of Biological Sciences, Nanyang Technological University Singapore, Singapore, Singapore

关键词: breast cancer;    PEMFs;    EMT;    patient-derived xenograft;    chorioallantoic membrane;    doxorubicin;   

DOI  :  10.3389/fonc.2022.892408

来源: DOAJ

【 授权许可】

Unknown